Amicogen Inc is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâ€™s products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company sells its products in domestic and overseas markets.

Employees

236

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-12	1,304.00 ₩	+0.69%	600,643
26-06-11	1,295.00 ₩	+2.13%	750,814
26-06-10	1,268.00 ₩	-3.13%	652,532
26-06-09	1,309.00 ₩	-0.46%	544,856
26-06-08	1,315.00 ₩	-6.61%	421,385

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-06-12			5-day change	1st Jan Change
1,304.00 ^KRW	+0.69%		-8.17%	-26.82%

05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	91.87B 60.61M 52.35M 48.24M 45.15M 84.62M 5.76B 85.93M 570M 222M 2.8B 227M 223M 9.71B	P/E Ratio 2024	-4.02x	P/E Ratio 2025	-3.28x
Enterprise Value	179B 118M 102M 93.87M 87.87M 165M 11.21B 167M 1.11B 432M 5.46B 443M 433M 18.89B	EV / Sales 2024	1.86x	EV / Sales 2025	4.43x
Free-Float	95.13%	Yield 2024 *	-	Yield 2025	-

05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-23	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-14	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-09-21	Amicogen, Inc.(KOSDAQ:A092040) added to S&P Global BMI Index	CI
25-08-20	Bio-Works Launches WorkBeads AffimAb Edge: Strategic Expansion in the Protein A Resin Market	CI
25-08-14	Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-11	Amicogen, Inc. announced that it has received KRW 7 billion in funding from BIFIDO Co., Ltd.	CI
25-05-14	Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-24	Amicogen, Inc.(KOSDAQ:A092040) dropped from S&P Global BMI Index	CI
25-03-19	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-12-09	An undisclosed buyer agreed to acquire an unknown stake in Amicogen Biopharm Co., Ltd. from Amicogen, Inc. for KRW 54.7 billion.	CI
24-11-20	Enzynomics Co., Ltd. completed the acquisition of 37.32% stake in SKINMED Co., Ltd. from Amicogen, Inc..	CI
24-11-14	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI

24-06-20	Bio-Works and Amicogen have concluded their technology transfer project.	AQ
21-09-10	Bio Works Technologies : Amicogen Inc enters into agreement to divest its ownership in Bio-Works	AQ
21-02-17	Bio Works Technologies : Works signs licensing agreement with Amicogen Inc to establish local manufacturing of agarose resins in South Korea	AQ

Amicogen, Inc. Stock

Stocks

A092040

KR7092040005

Biotechnology & Medical Research

Valuation: Amicogen, Inc.

Chart: Amicogen, Inc.

Latest news : Amicogen, Inc.

Press Releases: Amicogen, Inc.

News in other languages: Amicogen, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Amicogen, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+0.69%
1 week	-8.17%
Current month	-17.21%
1 month	-23.25%
3 months	-5.09%
6 months	-55.65%
Current year	-26.82%

1 week	1,218	1,405
1 month	1,218	1,971
Current year	1,160	2,300
1 year	1,160	4,440
3 years	1,160	10,250
5 years	1,160	23,500
10 years	1,160	24,825

Manager	Title	Age	Since
Jjeo Pyo CEO	Chief Executive Officer	53	-
Young-Chul Yoon PRN	Corporate Officer/Principal	55	2024-03-27
Chun-Gu Kim AUD	Comptroller/Controller/Auditor	69	2025-03-26

Director	Title	Age	Since
Jun-Ho Kim BRD	Director/Board Member	56	2025-02-25
Jjeo Pyo BRD	Director/Board Member	53	-
Young-Chul Yoon BRD	Director/Board Member	55	2024-03-27

Date	Insider	Type	Main position	Quantity	% Market Cap.
03-02	Ji-Seong So	Buy	Director	435	0.0006%
03-02	Young-Chul Yoon	Buy	Director	109	0.0002%
02-26	Eun-seong Hwang	Buy		4,000	0.0072%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMICOGEN, INC.	+0.69%	-8.17%	-67.07%	-86.67%	59.62M
ARGENX SE	+1.03%	+2.30%	+54.92%	+111.78%	55.58B
WUXI APPTEC CO., LTD.	+2.72%	+3.06%	+53.28%	+47.85%	43.47B
BIONTECH SE	+1.12%	+2.79%	-13.71%	-17.53%	22.64B
INSMED INCORPORATED	+1.17%	+3.85%	+1.00%	+401.79%	20.96B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-4.13%	+16.62%	-30.70%	15.79B
GENMAB A/S	+0.15%	+2.24%	+9.06%	-39.50%	15.3B
EXELIXIS, INC.	-0.69%	+0.82%	+27.17%	+178.31%	13.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+6.41%	+21.05%	-	11.74B
PHARMAESSENTIA CORPORATION	+1.61%	+1.17%	+90.79%	+212.97%	10.96B
Average	+1.69%	+0.79%	+19.31%	+86.48%	21B
Weighted average by Cap.	+1.71%	+1.60%	+33.74%	+100.69%

	2024	2025
Net sales	174B 115M 98.92M 91.16M 85.33M 160M 10.89B 162M 1.08B 420M 5.3B 430M 421M 18.35B	41.98B 27.7M 23.92M 22.04M 20.63M 38.67M 2.63B 39.27M 260M 101M 1.28B 104M 102M 4.44B
Net income	-52.79B -34.83M -30.08M -27.72M -25.95M -48.63M -3.31B -49.38M -327M -128M -1.61B -131M -128M -5.58B	-29.96B -19.77M -17.07M -15.73M -14.73M -27.6M -1.88B -28.02M -186M -72.42M -914M -74.18M -72.6M -3.17B
Net Debt	112B 73.57M 63.54M 58.55M 54.81M 103M 6.99B 104M 691M 270M 3.4B 276M 270M 11.79B	86.91B 57.34M 49.52M 45.63M 42.71M 80.05M 5.45B 81.29M 539M 210M 2.65B 215M 211M 9.18B